Mallinckrodt plc June 15th Short Interest Update

Mallinckrodt plc (NYSE:MNK) encountered a drop of 7.4% or -1,055,186 shares in the short positions. The number dropped from 14,178,406 on May 31,2016 to 13,123,220 on June 15,2016. The final interest is 12.1% of the floated stock. The days to cover figure of 9 can be arrived using the average daily exchange of 1,513,224 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Mallinckrodt plc (NYSE:MNK): The stock opened at $55.98 on Friday but the bulls could not build on the opening and the stock topped out at $57.82 for the day. The stock traded down to $55.65 during the day, due to lack of any buying support eventually closed down at $55.97 with a loss of -4.68% for the day. The stock had closed at $58.72 on the previous day. The total traded volume was 2,416,130 shares.

The company shares have dropped -51.61% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $127.00 and the one year low was seen on Mar 16, 2016. The 50-Day Moving Average price is $60.38 and the 200 Day Moving Average price is recorded at $63.93.

Mallinckrodt plc (NYSE:MNK) has tumbled 3.55% during the past week and has dropped 10.92% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.95%. Mallinckrodt plc (NYSE:MNK) has underperformed the index by 8.22% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.